Top 20 of Precursor Cell Lymphoblastic Leukemia-Lymphoma

Article title # Publications/# Citations

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

2005: BLEbert; MAGillette; TRGolub; ESLander; JPMesirov; VKMootha; SMukherjee; APaulovich; ... SLPomeroy; ASubramanian; PTamayo;

3414

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

1999: CDBloomfield; MACaligiuri; HColler; JRDowning; MGaasenbeek; TRGolub; CHuard; ESLander; ... MLLoh; JPMesirov; DKSlonim; PTamayo;

1190

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease.

2006: SAArmstrong; ICBlat; JPBrunet; SACarr; PAClemons; EDCrawford; TRGolub; SJHaggarty; ... HHieronymus; JLamb; ESLander; JLerner; JWModell; DPeck; MReich; KNRoss; ASubramanian; GWei; RWei; MJWrobel;

565

Diagnosis of multiple cancer types by shrunken centroids of gene expression.

2002: GChu; THastie; BNarasimhan; RTibshirani;

479

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

2002: FAversa; MCapanni; FFrassoni; MFMartelli; KPerruccio; SPosati; DRogaia; LRuggeri; ... WDShlomchik; ATosti; EUrbani; AVelardi;

333

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.

2007: ECoustan-Smith; JDDalton; JRDowning; WEEvans; KGirtman; SGoorha; JMa; SMathew; ... CBMiller; CGMullighan; SBPounds; CHPui; IRadtke; MVRelling; SAShurtleff; XSu;

308

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

2003: MCavazzana-Calvo; AFischer; CCFraser; SHacein-Bey-Abina; FLe Deist; EMcIntyre; IRadford; MSchmidt; ... JLVilleval; Cvon Kalle; NWulffraat;

258

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

2002: FGBehm; DCampana; CCheng; JRDowning; WEEvans; JLi; HLiu; RMahfouz; ... CNaeve; APatel; DPatel; CHPui; SCRaimondi; MVRelling; MERoss; SAShurtleff; DWilkins; WKWilliams; LWong; EJYeoh; XZhou;

258

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

2008: JAdickes; MGAnderson; JChen; SWElmore; SFesik; SJin; EFJohnson; KCMarsh; ... MJMitten; PNimmer; LRoberts; SHRosenberg; ARShoemaker; SKTahir; CTse; YXiao; XYang; HZhang;

250

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

2001: RCapdeville; BJDruker; JMFord; HKantarjian; SFReese; DJResta; CLSawyers; MTalpaz;

250

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

2001: SAArmstrong; MLden Boer; TRGolub; SJKorsmeyer; ESLander; MDMinden; RPieters; SESallan; LBSilverman; JEStaunton;

248

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

2006: MABlackwood-Chirchir; EBleickardt; TTChen; JCortes; APDecillis; NDonato; FHuang; VIyer; ... HKantarjian; CNicaise; JNicoll; SO'Brien; RPaquette; CLSawyers; NPShah; MTalpaz;

245

Treatment of acute lymphoblastic leukemia.

2006: WEEvans; CHPui;

238

Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.

1993: NEDavidson; SDesnoyers; SHKaufmann; YOttaviano; GGPoirier;

211

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

2005: MAzam; WBreitenstein; JBrüggen; LCallahan; LCatley; CCavazza; SWCowan-Jacob; GQDaley; ... DFabbro; GFendrich; DGGilliland; JDGriffin; EHall-Meyers; BHuntly; ALKung; PWManley; JMestan; AMohammed; DNeuberg; ARay; EWeisberg; RDWright;

195

Oncogenic transcription factors in the human acute leukemias.

1997: ATLook;

189

Support vector machine classification and validation of cancer tissue samples using microarray expression data.

2000: DWBednarski; NCristianini; NDuffy; TSFurey; DHaussler; MSchummer;

182

Graft-versus-leukemia reactions after bone marrow transplantation.

1990: RPGale; JMGoldman; MMHorowitz; JKersey; HJKolb; AARimm; ORingdén; CRozman; PMSondel; BSpeck;

180

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

2008: JDalton; JRDowning; TPHughes; MMLe Beau; JMa; CBMiller; CGMullighan; LAPhillips; ... CHPui; IRadtke; MVRelling; SAShurtleff; DWhite;

173

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

2006: MAlbitar; LAlland; KBhalla; KBochinski; JCortes; MDugan; FGiles; JDGriffin; ... AHochhaus; DHoelzer; HKantarjian; PManley; WMietlowski; SO'Brien; OGOttmann; PRae; CTanaka; BWassmann; LWunderle;

172